The requirement for rational drug design in the search for new agents that are active against parasitic protozoa prompted our in vitro studies with a group of 9-anilinoacridines. In vitro growth assays with Trypanosoma lewisi identified a series of C-i' alkylaminoacridines which possess previously unreported potent growth-inhibitory activities against T. kwisi at a concentration range of 0.1 to 1 ,uM. In contrast, several 9-anilinoacridines that possess acridine ring NH2 substituents at C-3 and C-6 were inactive against T. kwisi, but they possessed strong activity against Plasmodium fakciparum at a concentration range of 0.1 to 2.8 ,uM. In mammalian cells, amsacrine [4'-(9-acridinylamino)methanesulfon-m-anisidide] inhibits DNA topoisomerase II; however, amsacrine was only weakly active against T. lewisi. Such differences in the patterns of susceptibility of mammalian cells, T. lewisi, and P. falciparum to these 9-anilinoacridines may reflect enzyme differences between different parasites and mammalian cells that can be exploited by further improvements in drug design.
Parasitic protozoa belonging to the genera Trypanosoma and Plasmodium are responsible for three of the most severe tropical diseases known to affect humans: African trypanosomiasis (sleeping sickness), Chagas' disease, and malaria. These diseases, which are caused by Trypanosoma brucei subsp. gambiense or Trypanosoma brucei subsp. rhodesiense, Trypanosoma cruzi, and Plasmodium species, respectively, give rise to widespread infections of humans throughout Africa, South America, and southeastern Asia (10) .
Despite much progress in the development and evaluation of new methods of control and improved understanding of the epidemiology of trypanosomiases and malaria, treatment by chemotherapy has seen very little progress in recent years (7) . However, the U.S. Food and Drug Administration has recently approved the use of difluoromethylornithine (eflornithine hydrochloride) for the treatment of sleeping sickness (17) , and prelimi-nary clinical trials in western Africa (11) have shown that difluoromethylornithine can be used to successfully treat patients with T. brucei gambiense infection, although side effects resulting from use of the drug are still a common problem. The chemotherapeutic approaches to treating malaria are largely hampered by the development of parasite resistance to currently used drugs such as pyrimethamine, chloroquine, mefloquine, and quinine (12) . A 9-substituted 1-aza-acridine, pyronaridine, is being evaluated as an antimalarial agent in clinical trials (9) . Consequently, improved drug therapy of parasitic protozoal infections is still desirable, and rational approaches are needed to identify novel drug targets which can be specifically exploited in these protozoal cells.
Studies (20) . Trypanosomes possess a unique mitochondrial structure, the kinetoplast, and the DNA topoisomerases associated with the topological control of kinetoplast DNA may potentially be exploited as specific drug targets. In addition, the selective inhibition of nuclear trypanosomal DNA topoisomerase II may be exploitable in view of the observation that certain antitumor drugs can selectively inhibit different nuclear DNA topoisomerase II isozymes in mammalian cells (2) . Because malarial parasites do not possess a mitochondrial kinetoplast structure, differences between the nuclear DNA topoisomerases of these parasites and mammalian cells will have to be exploited in the design of new antimalarial agents targeted at the DNA topoisomerases in these organisms.
As part of an approach to inactivating novel parasitic protozoal targets, we screened and identified a series of anticancer drugs which possess in vitro trypanocidal and antimalarial activity against Trypanosoma lewisi and Plasmodium falciparum, respectively. A series of specific structural alterations to the parent compound produced a small number of highly active agents in these model systems. Initial structure-activity studies with these compounds are reported and discussed here.
MATERIALS AND METHODS
9-Anilinoacridines. The 9-anilinoacridine compounds were synthesized by the previously reported methods of Rewcastle et al. (13) . The compounds were purified by crystallization of their HCl salts from methanol-ethyl acetate. Purity and characterization were confirmed by thin-layer chromatography and nuclear magnetic resonance spectroscopy.
The compounds were prepared as stock solutions in 50% ethanol and were stored at 4°C in the dark.
Trypanosomes. T. lewisi parasites were isolated from tail blood that was obtained from naturally infected Kiore (Polynesian) rats (Rattus exulans) from Tiritiri Matangi Island, Tables 1 and 2 demonstrate that a series of 9-anilinoacridine derivatives (Fig. 1) which were initially developed as potential anticancer agents possess previously unreported potent antitrypanosomal and antimalarial activities.
By considering the compounds tested in this initial in vitro screening (Tables 1 and 2 Against P. falciparum (Table 2) , a similar active concentration range (0.1 to 2.8 ,uM) was observed with a number of the 9-anilinoacridine compounds. The introduction of a C-3,6 acridine ring substitution (compounds 9074 and 22761) appeared to increase the antimalarial effectiveness of this series of 9-anilinoacridines. It is interesting that compounds 9074 and 7567 possessed in vitro antimalarial activities (50% inhibitory concentrations of 0.1 and 2.8 ,uM, respectively), whereas they were both inactive against T. lewisi at concentrations of up to 10 ,uM in in vitro assays. This observation may be an indication of differences in parasite DNA topoisomerases, or it may reflect differences in drug transport into the parasite cells. At present, the number of compounds tested against P. falciparum is too small to enable greater structure-activity relationships to be reported. The structure-activity relationship observed within the small range of active 9-anilinoacridine compounds described here suggests that a specific intracellular biochemical or enzymatic system is the target of these drugs. Early studies with trypanosomal DNA topoisomerases have indicated that an ATP-independent type II enzyme is a potential target for several classes of drugs (6, 14, 16) explore and exploit differences in topoisomerases, and this view is supported by our findings on T. lewisi and P. falciparum, which show that quite minor alterations to topoisomerase inhibitors can have substantial effects on their actions.
As yet, the abilities of these compounds to selectively target parasite cells in vivo have not been addressed because of the preliminary in vitro nature of the tests described here. However, it should be possible to synthesize additional derivatives which incorporate substituents that are known to significantly reduce the toxicity of 9-anilinoacridines to mammalian cells (1, 4) . Whether these alterations will also reduce the antiparasitic effectiveness of the compounds remains to be established.
We are testing the 9-anilinoacridines described here and other new analogs that have been shown to possess in vitro activity against T. lewisi and P. falciparum as inhibitors of T. lewisi and P. falciparum DNA topoisomerases, respectively.
In this way, we aim to identify novel antitrypanosomal and antimalarial drugs with specificity for parasite DNA topoisomerases and to identify features of the drugs which will improve their activities.
